Doç.Dr. Senem Maral

Hakkında

Senem Maral, Hematoloji alanında Medipol Mega Üniversite Hastanesi doktor kadrosunda yer almaktadır.

Eğitim

• 2017
• ANKARA EĞİTİM ARAŞTIRMA HASTANESİ, HEMATOLOJİ
• 2012
• FATİH ÜNİVERSİTESİ, İÇ HASTALIKLARI
• 2006
• KOCAELİ ÜNİVERSİTESİ, TIP FAKÜLTESİ

Deneyim

• ANKARA ÇAMLICA SAĞLIK OCAĞI
• ANKARA ABDURRAHMAN YURTARSLAN ONKOLOJİ EĞİTİM VE ARAŞTIRMA HASTANESİ
• ANKARA SİNCAN F TİPİ CEZA İNFAZ KURUMLARI KAMPUS DEVLET HASTANESİ
• ANKARA DIŞKAPI YILDIRIM BEYAZIT EĞİTİM ARAŞTIRMA HASTANESİ

Bilimsel yayınlar

• SCI/SCI-E ve Diğer İndekslerde Yurt Dışı Eserleri:1.Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib. Maral S, Bakanay SM, Kucuksahin O, Dilek I.
• J Oncol Pharm Pract. 2019 Jul 30:1078155219863469. doi: 10.1177/1078155219863469
• 2. The rare coexistence of high titer inhibitor development and gastrointestinal stromal tumor in a patient with severe hemophilia: a case report. Yıldız, A., Şahin, O., Yayar, O., Öztürk, Ç. P., Öztürk, H. BA.Ozturk, Maral S., Okutan H., Albayrak, M. (2018). Transfus Apher Sci. 2018 Jun;57(3):398-400. doi: 10.1016/j.transci.2018.04.023. Epub 2018 Apr 26.
• 3. Dimethyl Sulfoxide-Induced Tonic Clonic Seizure and Cardiac Arrest During Infusion of Autologous Peripheral Blood Stem Cells. Maral S, Albayrak M, Pala C, Yildiz A, Sahin O, Ozturk HB. Cell Tissue Bank. 2018 Aug 11. doi: 10.1007/s10561-018-9718-x.
• 4. Is antimicrobial prophylaxis necessary for lymphoma patients? A single centre, real-life experience. Yıldız, A., Öztürk, H. B., Albayrak, M. Pala, Ç., Şahin O., Maral S., & Okutan, H. J Oncol Pharm Pract. 2018 Aug 22:1078155218795323. doi: 10.1177/1078155218795323.
• 5. Infections in patients with lymphoma: An analysis of incidence, relationship and risk factors. Yıldız A, Albayrak M, Pala Çiğdem, Şahin O, Afacan Öztürk H, Güneş G, Maral S, Okutan H. J Infect Dev Ctries. 2018 12:741-747. doi: 10.3855/jidc.10399.PMID: 31999632
• 6. Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate. Maral S, Bakanay SM, Yikilmaz AS, Dilek I. J Cancer Res Ther. 2018 Oct-Dec;14(6):1431-1433. doi: 10.4103/0973-1482.192762.
• 7. A Placebo-Controlled, Randomized, Double-Blinded, Cross-Over Phase I Clinical Study to Demonstrate Safety of Ankaferd Blood Stopper Topical Usage In Healthy Volunteers. Balcik OS, Koroglu M, Cipil H, Kaftan O, Maral S, Gurel A, Goker H, Haznedaroglu IC, Kosar A. UHOD 2012:22(4 );267-274 doi: 10.4999/uhod.10124
• 8. Acquired hemophilia with thrombosis in a cancer patient: an unusual presentation Maral S, Bakanay SM, Dilek I. Blood Coagul Fibrinolysis. 2018 Jan;29(1):129-130. doi: 10.1097/MBC.0000000000000670. PMID: 29095762.
• 9. Rare aggressive natural killer cell leukemia presented with leukopenia and disseminated intravascular coagulation—a diagnostic challenge. O Şahin, ÇP Öztürk, HBA Öztürk, S Maral- J Hematopathol 11, 5–7 (2018). https://doi.org/10.1007/s12308-017-0313-z
• 10. Refractory Thrombotic Thrombocytopenic Purpura in a patient with Kaposi sarcoma. Sahin O, Albayrak M, Yıldız A, Pala Ç, Aktas L, Maral S, Afacan Öztürk HB, Cömert P. Transfus Apher Sci. 2019 Apr;58(2):187-189. doi: 10.1016/j.transci.2019.02.003. Epub 2019 Mar 19.
• 11. A first time report on the coocurrence of sarcoidosis and ALK(-) CD30(+) anaplastic large cell lymphoma that is highly responsive to brentuximab vedotin treatment.Afacan Öztürk HB, Albayrak M, Pala Öztürk Ç, Yıldız A, Maral S, Önder E. J Oncol Pharm Pract. 2019 Mar 25:1078155219837331. doi: 10.1177/1078155219837331
• 12.CD81 Expression in the Differential Diagnosis of Chronic Lymphocytic Leukemia.Afacan-Öztürk HB, Falay M, Albayrak M, Yıldız A, Öztürk ҪP, Maral S, Özet G. Clin Lab. 2019 Mar 1;65(3). doi: 10.7754/Clin.Lab.2018.180802.
• 13.Matrix Metalloproteinases 2 and 9 Polymorphism in Patients With Myeloproliferative Diseases: A STROBE-Compliant Observational Study. Maral S, Acar M, Balcik OS, Uctepe E, Hatipoglu OF, Akdeniz D, Altun HU, Kosar A, Gunduz M, Gunduz E.Medicine (Baltimore). 2015 Apr;94(16):e732. doi: 10.1097/MD.0000000000000732.
• 14. CD25 Expression is Associated with Autoimmunity in Patients with CLL .Ozturk Hb, Yıldız A, Albayrak M, Pala C, Maral S, Falay M . UHOD. 2019:29;123-129 doi: 10.4999/uhod.193789
• 17. The least incompatible crossmatch red blood cell transfusion by biological compatibility test. Maral S, Bakanay SM, Akıncı S, Yıkılmaz AS, Comert P, Dilek I. GJTM.2019:4(2);154-157 DOI: 10.4103/GJTM.GJTM_37_19
• 18. An acute transverse myelitis attack after autologous stem cell transplantation: A rare case. Cömert P, Albayrak M, Yıldız A, Şahin O, Öztürk ÇP, Maral S, Güneş G, Afacan Öztürk HB, Sağlam B.Transfus Apher Sci. 2019 Jun;58(3):341-343. doi:10.1016/j.transci.2019.05.002. Epub 2019 May 14.
• 19. A rare case of diffuse large B-cell lymphoma-associated hemophagocytic lymphohistiocytosis. Malkan UY, Albayrak M, Yildiz A, Maral S, Afacan Ozturk HB, Comert P.J Oncol Pharm Pract. 2020 Jun 6:1078155220929750. doi: 10.1177/1078155220929750. Online ahead of print.
• 20. Prognostic Value of Baseline Serum Lactate Dehydrogenase Level in Patients With Hairy Cell Leukemia. Maral S, Albayrak M, Dagdas S, Yıldız A, Yıldırım R, Oz M, Pala C, Afacan Ozturk HB, Bay I, Ozet G, Dilek I.Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):e616-e621. doi: 10.1016/j.clml.2020.04.005. Epub 2020 Apr 22.PMID: 32418838
• 21. A Placebo-Controlled, Randomized, Double-Blinded, Cross-Over Phase I Clinical Study To Demonstrate Safety of Ankaferd Blood Stopper Topical Usage In Healthy Volunteers: 336 Balcik OS, Koroglu M, Cipil H, Kaftan O, Maral S, Gurel A, Goker H, Haznedaroglu IC, Kosar A. Int J Lab Hematol 2010;32:126-127.
• 22. Q fever as a rare cause of hemophagocytic lymphohistiocytosis: Case report. Sağlam B, Albayrak M, Acar A, Yıldız A, Maral S, Tığlıoğlu M, Battal İ, Şahin EN, Kuş A.Transfus Apher Sci. 2020 Aug;59(4):102747. doi: 10.1016/j.transci.2020.102747. Epub 2020 Feb 28.PMID: 32171685
• 23. Diffuse large B cell lymphoma progression with skin involvement: A case report. Akyol P, Albayrak M, Maral S, Canpolat F, Afacan Öztürk HB, Sağlam B, Tığlıoğlu M.J Tissue Viability. 2020 Aug;29(3):216-217. doi: 10.1016/j.jtv.2020.04.001. Epub 2020 Apr 9.PMID: 32340715
• 24. Synchronous detection of multiple myeloma and acute myeloid leukemia: A diagnostic and therapeutic challenge. Maral S, Albayrak M, Sahin O, Ozturk HBA, Han U, Falay M. J Oncol Pharm Pract. 2021 Mar;27(2):464-469. doi: 10.1177/1078155220932352. Epub 2020 Jun 17.
• 25. Primary Splenic Diffuse Large B Cell Lymphoma. Case Report and Literature Review. Öztürk, H.B.A., Albayrak, M., Pala, Ç. Yıldız S, Maral S, Şahin O, Cömert P,Han U. SN Compr. Clin. Med. 2, 2448–2451 (2020). https://doi.org/10.1007/s42399-020-00523-6
• 26. Transfusion in autoimmune hemolytic anemia: comparison of two different strategies. Maral S., AlbayrakM., YıldızA., ÖztürkH. B. A., Dilek I. (2020). Medical Science and Discovery, 7(8), 589-93. https://doi.org/10.36472/msd.v7i8.404
• 27. Modified R-IDARAM treatment in central nervous system lymphomas: A single centre experience. Maral S, Albayrak M, Pala C, Ozturk HBA, Yıldız A, Şahin O, Okutan H. Avicenna J Med. 2020: 10( 4): 227-231 DOI: 10.4103/ajm.ajm_59_19
• 28.Rare Entity in Chronic Myelocytic Leukemia: Coexistence of BCR ABL1 Translocation and JAK2 V617F Mutation. Case Report Sağlam B, Albayrak M, Yıldız A, Akyol P, Pala C,Maral S, Öztürk HBA, Tığlıoğlu M, Şahin O.SN Comprehensive Clinical Medicine (2020) 2:478–480 doi.org/10.1007/s42399-020-00252-w
• 29. The outcome of COVID-19 in patients with hematological malignancy. Tığlıoğlu P, Albayrak M, Tığlıoğlu M, Öztürk HBA, Aras MR, Sağlam B, Maral S.Memo. 2021 Dec 9:1-7. doi: 10.1007/s12254-021-00775-5.
• 30.A rare case of diffuse large B-cell lymphoma-associated hemophagocytic lymphohistiocytosis.Malkan UY, Albayrak M, Yildiz A, Maral S, Afacan Ozturk HB, Comert P. J Oncol Pharm Pract. 2021 Jan;27(1):250-252. doi: 10.1177/1078155220929750. Epub 2020 Jun 6.
• 31. Vitreous hemorrhage: A rare ophthalmic adverse effect due to imatinib treatment. Yılmaz F, Albayrak M, Tığlıoğlu P, Tığlıoğlu M, Sağlam B, Reis Aras M, Maral S, Afacan Öztürk HB. J Oncol Pharm Pract. 2021 Nov 13:10781552211060730. doi: 10.1177/10781552211060730.
• 32. Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.Gemici A, Ozkalemkas F, Dogu MH, Tekinalp A, Alacacioglu I, Guney T, Ince I, Geduk A, Cagliyan GA, Maral S, Serin I, Gunduz E, Karakus V, Bekoz HS, Eren R, Pinar IE, Gunes AK, Sargın FD, Sevindik OG. A Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):e686-e692. doi: 10.1016/j.clml.2021.04.004. Epub 2021 Apr 20.
• 33. Co-occurence of follicular lymphoma and Langerhans cell histiocytosis with primary parotid gland involvement: a case report. Albayrak A, Yıldız A, Albayrak M, Özhamam EU, Maral S. Hematol Transfus Cell Ther. 2021 Sep 15:S2531-1379(21)00127-9. doi: 10.1016/j.htct.2021.06.015. Epub ahead of print.
• 34. Hypercalcemia associated with the interaction between all trans retinoic acid and posaconazole in an acute promyelocytic leukemia case. Afacan Ozturk HB, Albayrak M, Maral S, Reis Aras M, Yilmaz F, Akyol P, Tiglioglu M, Malkan UY. J Oncol Pharm Pract. 2021 Dec;27(8):2027-2029. doi: 10.1177/10781552211007889. Epub 2021 Apr 13.
• 37. A rare case of pulmonary lymphomatoid granulomatosis complicated with venous thrombosis. Maral S, Albayrak M, Ozturk HBA, Incekara F, Yıldız A, Comert P, Albayrak A, Aras MR, Kaya S. Sarcoidosis Vasc Diffuse Lung Dis. 2022;38(4):e2021038. doi: 10.36141/svdld.v38i4.10140. Epub 2022 Jan 13.
• 38. Analysis of factors associated with the development of myelofibrosis in polycythemia vera and essential thrombocythemia patients: a single-center experience . Tığlıoğlu P, Albayrak M, Yıldız A, Tığlıoğlu M, Sağlam B, Aras MR, Yılmaz F, Maral S, Öztürk HBA, Malkan UY. J Hematopathol 2022. https://doi.org/10.1007/s12308-022-00488-6
• 39.The Importance of Tyrosine Kinase-Like Orphan Receptor 1 (ROR-1) in Chronic Lymphocytic Leukemia. Öztürk HBA, Albayrak M, Yıldız A, Maral S, Akyol P, Aras MR, Falay M. UHOD , 2021:31; 199-204 doi: 10.4999/uhod.215209
• 40.A Rare Entity in Chronic Myelocytic Leukemia: Coexistence of BCR ABL1 Translocation and JAK2 V617F Mutation. Case Report Sağlam B, Albayrak M, Yıldız A, Akyol P, Öztürk ÇP, Maral S, Öztürk HBA, Tığlıoğlu Mt, Şahin O. SN Comprehensive Clinical Medicine (2020) 2:478–480
• ULAKBİM ve Diğer İndekslerde Yurt içi Eserleri:
• 1.Thrombocytosis Associated with Iron Deficiency Anemia; Is It a Masked Myeloproliferative Disorder? Maral S. AMJ 2019:19(2);375 – 380 DOI: 10.17098/amj.570912
• 2. Thiol – Disulphide Homeostasis in Polycythemia Vera Yıkılmaz AS , Bakanay SM, Akinci S, Maral S, Mustafayev F , Alisik M, Erel O , Dilek I. Dicletıpdergisi 2019:46(2); 315 – 320 doi.org/10.5798/dicletip.574893

Çalışma yerleri 1